Some authors have reported favorable results during treatment with biological agents such as anti-TNF agents, the interleukin-6 antibody tocilizumab [5, 6], and anti-B cell antibodies such as rituximab [5] in patients with Takayasu’s disease. The gene discussed is TNF; the disease is Takayasu arteritis.